Max Planck Institute Places $426K Order with Geneart for Genes and Gene Variants

Max Planck Institute for Molecular Genetics awarded Geneart a contract to produce genes and gene variants for the project “Mutanom - Systems Biology of Genetic Diseases.” Genes will be developed over the next two...
Merck-s-biotech-manufacturing-site-in-Aubonne

Merck KGaA to Expand Aubonne, Switzerland Manufacturing Site

Merck KGaA, Darmstadt, Germany, said today it will carry out a €150 million ($168 million) expansion of its biologics manufacturing site at Aubonne, Switzerland, designed to help meet the growing demand for treatments by...
Plant expansion will include consolidation of all milling techniques. (© hemos - Fotolia.com)

SAFC to Invest $6.25M to Fortify Kansas Facility

Dry powder media batch production capacity will increase by 30%.

CMC Biologics, OncoSynergy Make Pact to Develop Materials for Toxicology Studies

CMC Biologics have inked an agreement with OncoSynergy to develop materials for IND-enabling toxicology studies and Phase I clinical trials.

CytoSorbents Wins $1M to Develop Purification Platform for Universal Blood Plasma

CytoSorbents has been awarded a $1M Small Business Technology Transfer (STTR) contract to support the development of a purification process that will allow the production of a "universal" blood plasma that doesn’t require cross-matching; CytoSorbents will work with Penn State University on the project

BMS to Idle 160 by Closing One Ireland Plant, Cutting Jobs at Another

Cruiserath plant in Dublin set to close by end of 2015, idling all 130 workers; another 30 to be axed at Swords.

Baxter Taps Sanquin for Plasma Fractionation

Netherlands-based blood supply foundation will provide up to 1.6 million liters of fractionation capacity annually while Baxter constructs new U.S. plant.

SurModics Opens 90,000 Sq. Ft. Manufacturing and Development Site in Alabama

The site handles microparticles, nanoparticles, liposomes, and implants for ER delivery of small molecules, peptides, proteins, and antibodies.

Sartorius Stedim Biotech Becomes Major Owner of AllPure Technologies

Sartorius Stedim Biotech signed a deal to acquire the majority stake in AllPure Technologies.

Recently Featured

Stay Connected

555,231FansLike
48,890FollowersFollow
Scroll Up